Osteogenesis Imperfecta Federation Europe’s Post

As part of RareCan's new Trial Matching service our team are having lots of conversations with people with rare and less common types of cancer about phase 1 trials. (As well as about later phase trials...) Coming from a non cancer background, I used to think of phase 1 trials only involving healthy volunteers. Here our Chief Scientific Officer Andy Hall talks about why phase 1 cancer trials involve patients. #cancer #cancerresearch #clinicaltrials

This is going to be a great conference! My talk will be a contrarian take, in a room full of many of my favorite contrarians: "Your Speech Is Freer Than You Think: The Irrational Risk Aversion of (Most) Academic Self-censorship" The crux of my argument will be that demand for truth, rigor, nuance, and "normie" takes is higher than people think and is rising, while self-censorship is reducing supply of such takes and research. Low supply and high demand means the price is high. The long-term incentives in academia are also generally for risk loving and for originality. All of this creates under-appreciated opportunity for people willing to venture into the fray. Most of the pushback you get is annoying at worst, not career existential*, and does not outweigh the above-described benefits. I will describe this theory in detail and then show examples from my career and careers of others. I'll also argue that anyone who has ever uttered something like "[Scientific Institution X] has lit its credibility on fire by [doing act of politically correct pandering Y]" is implicitly agreeing with my thesis. *My title includes the word "most" because I think there are three types of cases where getting into the fray comes with real career risk: when you are on the job market (it's easier to not hire someone, than to fire or not tenure someone, for dubious reasons), when you have a substantial career-risk comorbidity (e.g., being an adjunct, having marginal tenure case, being in a program at risk of elimination), and when you are pushing ideas or lines of inquiry that are deeply taboo or unpopular *in society as a whole* (not just in hyper-progressive corners of academia). But I will argue that most academic self-censorship fits into none of those cases, and that academic self-censorship is probably doing more damage to academia than direct censorship is (though obviously the latter encourages the former, so I'm not absolving the censors!). Free speech and academic freedom are useless if you don't use them! So, go forth and inquire openly! Come to the conference if you want to hear more. https://lnkd.in/gqQqJF5v

At the recent Victorian Translational SIMposium, Dr Chiara Santomauro discussed the concept of safety science and specifically Safety II - safety guided by adaptability. Watch the full presentation FREE on our website now: https://buff.ly/4i3vC3X

For the future generation with interest in nuclear-related paths, we welcome you tomorrow for the great webinar with quality experts

📣 📰 Come and get it - Vol. 3 of The Pulse where we recap key findings about what sets Pittsburgh's life sciences ecosystem apart and what actions are needed to capitalize on these opportunities. https://bit.ly/pulsevol3

The explosion in HHT research isn't a coincidence. It's the result of years of effort from our dedicated staff to growing the medical and scientific community focusing on this disease. From just around 50 attendees in 1996 to over 350 at our 15th Scientific Conference just a few weeks ago, we are committed to getting this disease the attention it deserves!

For a 5 minute introduction to the latest and greatest #automated #AI #Smart Tagging feature in Nested Knowledge, Inc., see this video! I built a Rapid Review on GLP-1 agonists in less than 20 minutes, and the AI did all the heavy lifting on Search and extracting Tags. a true transformation of the process to build out any review and give immediate findings!

At Nested Knowledge, our goal is to allow you to build collaborative, systematic processes to answer complex research questions. Core Smart Tags are the next step in speeding up your clinical evidence synthesis workflow. Learn more in this brief overview from our CEO, Kevin Kallmes

How do you effectively format the Research Strategy to help reviewers find the salient points? ✅ Master the R Series will show you! Our updated course addresses the new NIH simplified peer review framework and contains many new sample application components. https://zurl.co/asEY

In our new blog post, I talk about our recent work that gives us powerful new insight into the shared immune responses to exposures.